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Introduction
Clinical trials of tocilizumab(TCZ) have verified its efficacy
and safety in systemic juvenile idiopathic arthritis (sJIA),
but there are many outstanding issues, relevant to the real
clinical practice.
Objectives
to investigate TCZ in pts with sJIA depending on the age
of disease onset,duration of disease, the number of active
joints, the number of systemic features and previous
biologics(B).
Methods
In prospective study were included 45 pts(19b/26g) with
sJIA refractory to conventional treatment, who was treated
by TCZ from 9 months to 54 months. At baseline mean
age of 6.25(2.0-17.8)yrs; mean disease duration of 4.5(0.3-
15.9)yrs. TCZ used as the 1st B in 28 pts, 2nd – in 12, 3rd –
in 5. 37.8% pts previously received B:TNF-ingibitors-17,
abatacept–2, rituximab–3. 41 pts(91.1%) had arthritis at
the baseline. Systemic features were observed in 40(88.9%)
pts. Mean number of systemic manifestations(NSM) was
2.82 (1.5;6). 2 pts had MAS before of TCZ initiation.
Retrospectively all pts were separated into the groups
depending on the age of manifestation of disease (before
3 yrs/older 3 yrs -22/23), duration of disease (less than
3 yrs/more – 20/25), the number of active joints (less than
10/more–22/23), the number of active systemic features
(NSM 0 – 13 pts, 1/2 - 10, 3/4 - 12, 5/6 – 10), and
previous B (B-naïve/previous B-28/17). Efficacy of TCZ
therapy was evaluated in accordance to ACRpedi criteria
in 1, 3, 6, 9, 12 and every 6 months of treatment later.
Results
36 pts continue the treatment, mean duration
27.4 months(9;54). In 9 pts TCZ was cancelled due to
serious adverse effects(5), another reasons(4). All pts
achieved more than 30-50% improvement by ACRpedi
criteria. We found no significant differences in efficacy
parameters at the response to therapy depending on the
investigated factors. However, pts who had early mani-
festation of disease, long disease duration, large NSM
achieved good response on arthicular status more
slowly. Also we observed some increasing of disease
activity in all groups between 30-36 months of therapy.
Steady improvement allowed to decrease prednisolone
(PR) dose in all pts, to cancel PR in 19.4% pts, to can-
cel NSAIDs in 14% pts. 9 pts achieved inactive disease
status. Adverse events were observed independently of
investigated factors and included postinfusion reactions
(vomiting-1, headache-2, sore throat-4, chestpain-4,
blood pressure increasing-1, eczema-2), infections
(upper respiratory infections-16, bronchitis-1,
pneumonia-2, gastroenteritis-1, ears ’ infections-3,
periodontitis-2), temporary laboratory abnormalities
(neutropenia-21, thrombocytopenia-8, IgG decreasing -10,
hyperbilirubinemia-3, elevated transaminases-7). We have
observed some SAE: infusion reaction (5); severe infections
– varicella (2), atypical pneumonia (1), tuberculosis(1).
MAS observed in 4 pts (1-after respiratory infection, 1-
after elective surgery, 1-after increase interval between
infusion more than 4 weeks, 1-unknown reason), in all
case of MAS TCZ was continued.
Conclusion
TCZ is the best choice among B at sJIA in Pts indepen-
dently on the age of manifestation of disease, duration
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active systemic features, previous B. Careful monitoring
provided an acceptable safety profile of TCZ in the pts
with sJIA. TCZ was well tolerated, and the majority of
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